1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Nasdaq Copenhagen  -  05/25 10:59:43 am EDT
738.60 DKK   -1.10%
05/27NOVO NORDISK : Berenberg reaffirms its Neutral rating
MD
05/24NOVO NORDISK : Deutsche Bank remains its Buy rating
MD
05/23Novo Nordisk A/S – Share repurchase programme
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Danish Pharmaceutical Company Novo Nordisk Expands at Home Via $2.6 Billion Investment on Manufacturing

12/13/2021 | 04:24am EDT


© MT Newswires 2021
All news about NOVO NORDISK A/S
05/27NOVO NORDISK : Berenberg reaffirms its Neutral rating
MD
05/24NOVO NORDISK : Deutsche Bank remains its Buy rating
MD
05/23Novo Nordisk A/S – Share repurchase programme
GL
05/20European ADRs Move Sharply Higher in Friday Trading
MT
05/20NOVO NORDISK : Berenberg remains Neutral
MD
05/16European ADRs Move Higher in Monday Trading
MT
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/16NOVO NORDISK A/S : Share repurchase programme
GL
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
RE
05/12NOVO NORDISK : Barclays gives a Buy rating
MD
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 166 B 23 931 M 23 931 M
Net income 2022 52 875 M 7 614 M 7 614 M
Net cash 2022 4 087 M 589 M 589 M
P/E ratio 2022 31,5x
Yield 2022 1,59%
Capitalization 11 648 B 1 677 B 1 677 B
EV / Sales 2022 70,1x
EV / Sales 2023 62,1x
Nbr of Employees 49 295
Free-Float 70,9%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 748,17 DKK
Average target price 875,38 DKK
Spread / Average Target 17,0%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S0.49%1 677 391
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098